Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 19, 2023 - Issue 5
Submit an article Journal homepage
1,149
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What is the significance of the pharmacokinetic profile and potential drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine?

Sara Bettontea Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital, Basel, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
,
Mattia Bertona Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital, Basel, Switzerland;b Faculty of Medicine, University of Basel, Basel, SwitzerlandView further author information
&
Catia Marzolinia Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital, Basel, Switzerland;b Faculty of Medicine, University of Basel, Basel, Switzerland;c Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UKCorrespondence[email protected]
View further author information
Pages 243-247 | Received 22 Mar 2023, Accepted 07 Jun 2023, Published online: 13 Jun 2023

References

  • US. Food and drug administration. Cabenuva product label. 2023 Mar. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf
  • European Medicines Agency. Rekambys summary of product characteristics. 2023 Mar. Available from: https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf
  • European Medicines Agency. Vocabria summary of product characteristics. 2023 Mar. Available from: https://www.ema.europa.eu/en/documents/product-information/vocabria-epar-product-information_en.pdf
  • Jucker BM, Fuchs EJ, Lee S, et al. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers. Br J Clin Pharmacol. 2021;88(4):1655–1666. doi: 10.1111/bcp.14977
  • Hodge D, Back DJ, Gibbons S, et al. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60(7):835–853. doi: 10.1007/s40262-021-01005-1
  • Thoueille P, Alves Saldanha S, Schaller F, et al. Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland. Pharmaceutics. 2022;14(8):1588. doi: 10.3390/pharmaceutics14081588
  • Bettonte S, Berton M, Stader F, et al. Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modelling study. Clin Infect Dis. 2022;76(7):1225–1236. [epub ahead print]. doi: 10.1093/cid/ciac901
  • Landovitz RJ, Li S, Eron JJ, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–481. doi: 10.1016/S2352-3018(20)30106-5
  • Aouri M, Barcelo C, Guidi M, et al. Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2017;61(1):e00899–16. doi: 10.1128/AAC.00899-16
  • Wagner C, Pan Y, Hsu V, et al. Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA. Clin Pharmacokinet. 2016;55(4):475–483. doi: 10.1007/s40262-015-0330-y
  • Taskar K, Patel P, Cozens S, et al. Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of cabotegravir, International Workshop on Clinical Pharmacology of HIV, hepatitis, and other antiviral drugs. Noordwijk 14-16 May 2019, abstract 18.
  • Liverpool HIV Drug Interactions website. 2023 Mar. Available from: https://www.hiv-druginteractions.org
  • Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother. 2017;61(10):e00487–e517. doi: 10.1128/AAC.00487-17
  • Van Heeswijk R, Hoetelmans R, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon 20-22 Apr, 2006, abstract 74.
  • Ford SL, Lou Y, Lewis N, et al. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. Antivir Ther. 2019;24(4):301–308. doi: 10.3851/IMP3306
  • Crauwels H, van Heeswijk R, Kestens D, et al. The pharmacokinetic interaction between rifabutin and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor. 17th International AIDS conference, Mexico 3-8 Aug 2008, abstract TUPE0080.
  • Bettonte S, Berton M, Stader F, et al. Intramuscular cabotegravir/rilpivirine concentrations after switching from efavirenz. 30th Conference on Retroviruses and Opportunistic Infections, Seattle 19-22 Feb 2023, abstract 508.
  • Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67(5):481–486. doi: 10.1097/QAI.0000000000000301
  • Bettonte S, Berton M, Marzolini C. Magnitude of drug-drug interactions in special populations. Pharmaceutics. 2022;14(4):789. doi: 10.3390/pharmaceutics14040789
  • Patel P, Ford SL, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2023;24(5):568–579. doi: 10.1111/hiv.13439

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.